Innovations for topical treatment of cutaneous leishmaniasis

• Grant number: 17/08390-3
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: February 01, 2018
• End date: December 31, 2018
• Field of knowledge: Health Sciences - Pharmacy - Pharmaceutical Technology
• Principal Investigator: Fernanda Mansano Carbinatto
• Grantee: Fernanda Mansano Carbinatto
• Company: Biosmart Nanotechnology Ltda
• CNAE: Fabricação de produtos farmoquímicos
• Associated researchers: CAMILA INDIANI DE OLIVEIRA ; Hernane da Silva Barud ; Marlus Chorilli
• Associated scholarship(s): 18/09773-6 - Innovation for topical treatment of Cutaneous Leishmaniasis, BP.TT; 18/02789-4 - Innovations for topical treatment of Cutaneous Leishmaniasis, BP.TT; 18/02775-3 - Innovations for topical treatment of Cutaneous Leishmaniasis, BP.PIPE

Abstract

Tegumentary Leishmaniasis is an infectious disease with low lethality, not contagious, caused by a protozoan of the genus Leishmania, in Brazil, usually caused by Leishmania amazonensis, with several and increasing cases distributed throughout the national territory. Since 1915 to the present day the main form of treatment involves the administration of pentavalent antimonial or amphotericin B. Both treatments have several side effects that reduce the quality of life of patients. Since leishmaniasis therapies are scarce and all have numerous side effects, impairing and reducing the quality life of patient, it is necessary to develop new alternatives for the treatment of this disease. The present proposal aims at the development of a bio-curative for topical therapy of cutaneous leishmaniasis using bacterial cellulose matrix with the incorporation of a natural compound that shows antileishmanicidal activity, curcumin. The development of bacterial cellulose bio-curatives with the incorporation of curcumin formulations presents an innovative character and a promising alternative with economic viability for topical treatments of cutaneous leishmaniasis in relation to the other treatments available in the market. (AU)